Current Report Filing (8-k)
September 13 2019 - 6:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): September 12, 2019
(Exact
name of registrant as specified in its charter)
|
Nevada
|
|
001-38015
|
|
27-1865814
|
|
(State
or other jurisdiction of incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification No.)
|
3900
Paseo del Sol
Santa
Fe, New Mexico 87507
(Address of
Principal Executive Offices) (Zip Code)
Registrant’s
telephone number, including area code: (505) 438-2576
Former
name or former address, if changed since last report
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
|
Common Stock, par
value $0.001 per share
|
|
SGLB
|
|
The NASDAQ Stock
Market LLC
|
|
Warrants to Purchase
Common Stock, par value $0.001 per share
|
|
SGLBW
|
|
The NASDAQ Stock
Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth
company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard: Transfer of Listing
On
September 12, 2019, Sigma Labs, Inc. (“we,” “our,” “us,” “Sigma,” or the “Company”)
received notice from The Nasdaq Stock Market (“Nasdaq”) that the closing bid price for our common stock had been below
$1.00 per share for the last 30 consecutive business days, and that the Company therefore is not in compliance with the minimum
bid price requirement for continued inclusion on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The notice indicates
that the Company has 180 calendar days, or until March 10, 2020, to regain compliance with this requirement.
The
Company can regain compliance with the $1.00 minimum bid price requirement if the closing bid price of the Company’s common
stock is at least $1.00 for a minimum of ten consecutive business days during the 180-day compliance period. If the Company does
not regain compliance during the initial compliance period, the Company may be eligible for additional time to regain compliance.
To qualify, the Company will be required to meet the continued listing requirement for market value of its publicly held shares
and all other Nasdaq initial listing standards, except the bid price requirement, and will need to provide written notice to Nasdaq
of the Company’s intention to cure the deficiency during the second compliance period by effecting a reverse stock split,
if necessary. If the Company meets these requirements, we expect that Nasdaq will grant the Company the additional 180 calendar
days to regain compliance with the minimum bid price requirement. If it appears to Nasdaq that the Company will not be able to
cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will notify us that the Company’s common stock
will be subject to delisting.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Date: September 12, 2019
|
SIGMA LABS, INC.
|
|
|
|
|
|
|
By:
|
/s/
John Rice
|
|
|
Name:
|
John Rice
|
|
|
Title:
|
President and Chief Executive Officer
|
Sigma Labs (NASDAQ:SGLB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sigma Labs (NASDAQ:SGLB)
Historical Stock Chart
From Apr 2023 to Apr 2024
